STSP 0601
Alternative Names: Factor X activator injection STSP-0601; STSP-0601; STSP-0601 for injectionLatest Information Update: 18 Apr 2024
At a glance
- Originator Staidson Beijing BioPharmaceuticals
- Class Antihaemorrhagics; Blood coagulation factors; Proteins
- Mechanism of Action Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haemophilia A; Haemophilia B
Most Recent Events
- 18 Mar 2024 Staidson (Beijing) Biopharmaceuticals initiates a phase II trial in Haemophilia A and Haemophilia B (IV) in China (NCT06289166)
- 01 Mar 2024 Staidson Biopharmaceuticals plans a phase II trial for Haemophilia A and Haemophilia B in China (Parenteral) in Febraury 2024 (NCT06289166)
- 25 Aug 2023 Staidson Beijing BioPharmaceuticals completes the phase-II trial in Haemophilia B in China (IV) (NCT05619926)